7 and Cancer and Leukemia Group B (CALGB) 90206 8 indicated significant improvements in PFS for bevacizumab plus interferon-α compared with interferon-α alone. This effect applied to patients in ...

Despite the challenges, there's still plenty of interest in IL-2 as a cancer therapy ... Other projects include a PD-L1/interferon alpha which is due to generate a clinical candidate before ...

Interferon alpha is a well-validated therapeutic and was one of the first immunotherapies to be approved for cancer treatment. Interferon has established single-agent anticancer activity in ...